These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 24492309)

  • 1. HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design.
    de Goeij BE; Peipp M; de Haij S; van den Brink EN; Kellner C; Riedl T; de Jong R; Vink T; Strumane K; Bleeker WK; Parren PW
    MAbs; 2014; 6(2):392-402. PubMed ID: 24492309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs.
    Andreev J; Thambi N; Perez Bay AE; Delfino F; Martin J; Kelly MP; Kirshner JR; Rafique A; Kunz A; Nittoli T; MacDonald D; Daly C; Olson W; Thurston G
    Mol Cancer Ther; 2017 Apr; 16(4):681-693. PubMed ID: 28108597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells.
    Kang JC; Poovassery JS; Bansal P; You S; Manjarres IM; Ober RJ; Ward ES
    MAbs; 2014; 6(2):340-53. PubMed ID: 24492289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy.
    Li JY; Perry SR; Muniz-Medina V; Wang X; Wetzel LK; Rebelatto MC; Hinrichs MJ; Bezabeh BZ; Fleming RL; Dimasi N; Feng H; Toader D; Yuan AQ; Xu L; Lin J; Gao C; Wu H; Dixit R; Osbourn JK; Coats SR
    Cancer Cell; 2016 Jan; 29(1):117-29. PubMed ID: 26766593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
    Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
    Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Near-Infrared Photochemoimmunotherapy by Photoactivatable Bifunctional Antibody-Drug Conjugates Targeting Human Epidermal Growth Factor Receptor 2 Positive Cancer.
    Ito K; Mitsunaga M; Nishimura T; Saruta M; Iwamoto T; Kobayashi H; Tajiri H
    Bioconjug Chem; 2017 May; 28(5):1458-1469. PubMed ID: 28402624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human kappa light chain targeted Pseudomonas exotoxin A--identifying human antibodies and Fab fragments with favorable characteristics for antibody-drug conjugate development.
    Kellner C; Bleeker WK; Lammerts van Bueren JJ; Staudinger M; Klausz K; Derer S; Glorius P; Muskulus A; de Goeij BE; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
    J Immunol Methods; 2011 Aug; 371(1-2):122-33. PubMed ID: 21756911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High turnover of tissue factor enables efficient intracellular delivery of antibody-drug conjugates.
    de Goeij BE; Satijn D; Freitag CM; Wubbolts R; Bleeker WK; Khasanov A; Zhu T; Chen G; Miao D; van Berkel PH; Parren PW
    Mol Cancer Ther; 2015 May; 14(5):1130-40. PubMed ID: 25724665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and Characterization of a Humanized Anti-HER2 Antibody HuA21 with Potent Anti-Tumor Properties in Breast Cancer Cells.
    Li R; Hu S; Chang Y; Zhang Z; Zha Z; Huang H; Shen G; Liu J; Song L; Wei W
    Int J Mol Sci; 2016 Apr; 17(4):563. PubMed ID: 27092488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hsp90 inhibition and co-incubation with pertuzumab induce internalization and degradation of trastuzumab: Implications for use of T-DM1.
    Skeie M; Nikolaysen F; Chitano Y; Stang E
    J Cell Mol Med; 2020 Sep; 24(17):10258-10262. PubMed ID: 32672902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.
    Ogitani Y; Hagihara K; Oitate M; Naito H; Agatsuma T
    Cancer Sci; 2016 Jul; 107(7):1039-46. PubMed ID: 27166974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1).
    Diessner J; Bruttel V; Stein RG; Horn E; Häusler SF; Dietl J; Hönig A; Wischhusen J
    Cell Death Dis; 2014 Mar; 5(3):e1149. PubMed ID: 24675467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design.
    Maass KF; Kulkarni C; Betts AM; Wittrup KD
    AAPS J; 2016 May; 18(3):635-46. PubMed ID: 26912181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
    Corrigan PA; Cicci TA; Auten JJ; Lowe DK
    Ann Pharmacother; 2014 Nov; 48(11):1484-93. PubMed ID: 25082874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models.
    Kuo WY; Hsu HJ; Wu CY; Chen HS; Chou YC; Tsou YL; Peng HP; Jian JW; Yu CM; Chiu YK; Chen IC; Tung CP; Hsiao M; Lin CL; Wang YA; Wang AH; Yang AS
    MAbs; 2019 Jan; 11(1):153-165. PubMed ID: 30365359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression.
    Menderes G; Bonazzoli E; Bellone S; Black J; Altwerger G; Masserdotti A; Pettinella F; Zammataro L; Buza N; Hui P; Wong S; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2017 Jul; 146(1):179-186. PubMed ID: 28473206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simulating the Selection of Resistant Cells with Bystander Killing and Antibody Coadministration in Heterogeneous Human Epidermal Growth Factor Receptor 2-Positive Tumors.
    Menezes B; Linderman JJ; Thurber GM
    Drug Metab Dispos; 2022 Jan; 50(1):8-16. PubMed ID: 34649966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polyclonal Antibody against Different Extracellular Subdomains of HER2 Induces Tumor Growth Inhibition in vitro.
    Hosseini Ghatar R; Soltantoyeh T; Bahadori M; Khoshnoodi J; Golsaz Shirazi F; Jeddi Tehrani M; Amiri MM; Shokri F
    Iran J Immunol; 2017 Sep; 14(3):200-214. PubMed ID: 28919583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates.
    Jackson D; Atkinson J; Guevara CI; Zhang C; Kery V; Moon SJ; Virata C; Yang P; Lowe C; Pinkstaff J; Cho H; Knudsen N; Manibusan A; Tian F; Sun Y; Lu Y; Sellers A; Jia XC; Joseph I; Anand B; Morrison K; Pereira DS; Stover D
    PLoS One; 2014; 9(1):e83865. PubMed ID: 24454709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity.
    Yao X; Jiang J; Wang X; Huang C; Li D; Xie K; Xu Q; Li H; Li Z; Lou L; Fang J
    Breast Cancer Res Treat; 2015 Aug; 153(1):123-33. PubMed ID: 26253944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.